Ottawa has inked some more deals to ensure a steady supply of COVID-19 vaccines once available.
Prime Minister Justin Trudeau announced a deal has been struck with the pharma companies Johnson & Johnson and Novavax to procure millions of doses of potential vaccines. These agreements add to those struck with Pfizer and Moderna earlier this year.
Trudeau says the additional agreements mean Canadians now have secured 190 million doses between the four companies. “As we continue to work together to limit the impact of the COVID-19 pandemic on the health of Canadians, as well as its social and economic effects, we must also maximize our chances of defeating the virus,” said Trudeau Monday. “To do this, we need to invest in the development of several promising vaccines and ensure that we can manufacture and distribute the vaccine to as many Canadians as possible, as quickly as possible. That is how we will move forward on a sustainable path to a full recovery.”
The Prime Minister also announced Ottawa will fund the establishment of a new biomanufacturing facility at the Human Health Therapeutics Research Centre in Montreal to ramp up vaccine manufacturing once one becomes available.
There is currently no effective vaccine approved to prevent COVID-19. Many are in clinical trials or under development.
The Federal Government is also securing the equipment and supplies needed to package the vaccine, along with the syringes, needles, and alcohol swabs required.